Operator
Thank you for standing by. This is the conference operator. Welcome to Zymeworks conference call and webcast to discuss the acquisition of Theravance Biopharma. (Operator Instructions) The conference is being recorded. I would now like to turn the conference over to Shrinal Inamdar, Vice President of Investor Relations. Shrinal, please go ahead.
Shrinal Inamdar
VP of Investor Relations
Thank you, operator. Good afternoon, everyone, and thank you for joining. During today’s call, Ken Galbraith, our Chair and CEO, will provide an overview of the strategic rationale for the proposed acquisition of Theravance Biopharma by Zymeworks as announced by press release this morning.
Scott Platshon, our Chief Business Officer, will then provide a deeper understanding of Theravance’s business and the value of its underlying assets and cash flows. Lastly, Kristin Stafford, our Chief Financial Officer, will provide an overview of the key terms of the non-recourse financing with OMERS Life Sciences, and then we will open up the floor for Q&A at the end.
As usual, I’d like to remind you that this call will contain forward-looking statements, including, without limitation, those forward-looking statements identified in our slides and the accompanying oral commentary. Forward-looking statements are based on our current expectations and various
GIPHY App Key not set. Please check settings